| 235.02 -2.77 (-1.16%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 293.58 | 1-year : | 342.9 |
| Resists | First : | 251.35 | Second : | 293.58 |
| Pivot price | 215.69  |
|||
| Supports | First : | 210.61 |
Second : | 185.42 |
| MAs | MA(5) : | 235.43 |
MA(20) : | 213.51 |
| MA(100) : | 181.63 |
MA(250) : | 195.81 |
|
| MACD | MACD : | 11.7 |
Signal : | 8.9 |
| %K %D | K(14,3) : | 79.2 |
D(3) : | 84.6 |
| RSI | RSI(14): 67.8 |
|||
| 52-week | High : | 251.35 | Low : | 154.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IQV ] has closed below upper band by 19.4%. Bollinger Bands are 139.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 238.19 - 239.48 | 239.48 - 240.56 |
| Low: | 227.78 - 229.4 | 229.4 - 230.75 |
| Close: | 232.55 - 235.05 | 235.05 - 237.13 |
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Fri, 31 Jul 2026
Iqvia EVP, general counsel Eric Sherbet sells $1.25m in stock - Investing.com
Fri, 31 Jul 2026
IQVIA SVP Keriann Cherofsky sells $136,827 in company stock - Investing.com
Fri, 31 Jul 2026
IQVIA Holdings Inc. (NYSE: IQV) SVP reports sale of 558 common shares - Stock Titan
Fri, 31 Jul 2026
IQVIA Holdings (NYSE: IQV) EVP reports sale of 5,000 common shares - Stock Titan
Fri, 31 Jul 2026
IQVIA Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Thu, 30 Jul 2026
Is IQVIA Holdings Inc (IQV) a Bargain After 4.0% Drop? GF Value Says Undervalued - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 167 (M) |
| Shares Float | 159 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 103.9 (%) |
| Shares Short | 5,260 (K) |
| Shares Short P.Month | 5,030 (K) |
| EPS | 8.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 37.27 |
| Profit Margin | 8.3 % |
| Operating Margin | 13.6 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 22.4 % |
| Qtrly Rev. Growth | 8.3 % |
| Gross Profit (p.s.) | 32.89 |
| Sales Per Share | 99.64 |
| EBITDA (p.s.) | 17.97 |
| Qtrly Earnings Growth | 15 % |
| Operating Cash Flow | 2,700 (M) |
| Levered Free Cash Flow | 2,280 (M) |
| PE Ratio | 29.19 |
| PEG Ratio | 0.8 |
| Price to Book value | 6.3 |
| Price to Sales | 2.35 |
| Price to Cash Flow | 14.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|